Compare Newegg Commerce Inc (NEGG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs Sanofi SA — how do they compare? Newegg Commerce Inc trades at $11.7 (market cap $243.30M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 391.2× Newegg Commerce Inc's market cap, and Sanofi SA pays a 6.01% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newegg Commerce Inc for 14 Days and Sanofi SA for 94 Days on average.
| NEGG | SNY | |
|---|---|---|
Market Cap | $243.30M | $95.18B |
Volume | 41,252 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $52.34 |
52-Week Low | $11.49 | $39.51 |
Typical Hold Time | 14 Days | 94 Days |
Enterprise Value | $213.53M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $11.58, down 3.58% today, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 projections. Recent partnerships with Western Digital and HPE highlight strategic moves in AI and enterprise IT markets, while insider selling has created near-term pressure.
The stock presents a mixed picture with improving profitability but significant execution risks. While analyst consensus remains bullish with 100% buy ratings, the $7.75 price target suggests 33% downside from current levels. Key risks include volatile cash flows, competitive e-commerce pressures, and the need to sustain recent margin improvements.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
